CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - CRISPR Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 8:15 a.m. PT in San Francisco [1] Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on developing gene-based medicines for serious diseases, evolving from a research-stage organization to an industry leader [3] - The company achieved a historic milestone with the approval of CASGEVY (exa-cel), the world's first CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia [3] - CRISPR Therapeutics has a diversified pipeline targeting hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune diseases, and rare diseases [3] - The company is advancing its gene editing capabilities through the development of SyNTase™, a proprietary platform for precise and efficient gene correction [3] - Strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals, are established to enhance its impact [3] - The company is headquartered in Zug, Switzerland, with R&D operations in Boston, Massachusetts, and San Francisco, California [3]